GENFIT : Analyse de l AI sur Genfit

osaffer

13 novembre 2024 •13:19

Based on the information provided, here are the perspectives for GENFIT regarding the treatment of Primary Sclerosing Cholangitis (PSC) with elafibranor:

Ongoing Clinical Trial: GENFIT is currently conducting a study to assess the safety and effectiveness of elafibranor in adult participants with PSC1
. This indicates that the company is actively pursuing the development of elafibranor for PSC treatment.
Potential Expansion of Indications: Elafibranor has already received approval for Primary Biliary Cholangitis (PBC) in the US and EU3
5
. The ongoing research for PSC suggests GENFIT is aiming to expand the drug's indications, which could potentially increase its market reach and revenue potential.
Mechanism of Action: Elafibranor is a dual peroxisome activated receptor (PPAR) alpha/delta agonist, which targets multiple cell types and biological processes involved in cholestatic liver diseases2
. This mechanism could be beneficial for PSC patients, as it addresses cholestasis, bile toxicity, inflammation, and fibrosis.
Potential First-in-Class Treatment: If successful, elafibranor could become a first-in-class treatment for PSC, as it has for PBC. This could give GENFIT a significant advantage in the market for rare liver diseases.
Building on PBC Success: The positive results and regulatory approvals for elafibranor in PBC provide a strong foundation for its potential in PSC. The drug has demonstrated efficacy in improving liver function and reducing disease progression in PBC patients4
, which could translate to benefits for PSC patients as well.
Addressing an Unmet Need: PSC is a rare disease with limited treatment options. If elafibranor proves effective, it could address a significant unmet medical need, potentially leading to rapid adoption and favorable pricing.
Potential for Additional Revenue Streams: Success in PSC would open up a new revenue stream for GENFIT, complementing the existing and potential future revenues from elafibranor's use in PBC.
Long-term Growth Opportunity: The development of elafibranor for PSC represents a long-term growth opportunity for GENFIT, as clinical trials and potential regulatory approvals typically take several years.

While these perspectives are promising, it's important to note that the success of elafibranor in PSC will depend on the results of the ongoing clinical trials. The outcomes of these studies will be crucial in determining the drug's efficacy and safety profile in PSC patients, and ultimately, its potential for regulatory approval and commercial success in this indication.

veg468

13 novembre 2024 •14:38

Sur T3, Genfit a dépensé aux alentours de 13,3 M .
Ce sont les PH3 qui sont vraiment coûteuses.
Genfit n’en a pas en cours

On peut douter qu’ils en mènent 3-4-5 de front.
Sauf pipe-line PH2 avec des résultats exceptionnels.
Genfit n’en est pas encore là.

La trésorerie devrait s’allonger et durer plus que n’annoncent certains oiseaux